Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

Background The combination of bortezomib, melphalan, and prednisone is a standard
treatment for patients with newly diagnosed multiple myeloma who are ineligible for …

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly
reduced risk of progression/death versus lenalidomide/dexamethasone alone in …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …

Methods Patients ineligible for high-dose chemotherapy with autologous stem cell
transplantation due to age≥ 65 years or comorbidities were randomized 1: 1 to Rd±DARA …

Background In the primary analysis of the phase 3 MAIA trial (median follow-up 28· 0
months), a significant improvement in progression-free survival was observed with …